PXDT Pixie Dust Technologies Inc

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of December, 2023

 

Commission File Number 001-41749

 

PIXIE DUST TECHNOLOGIES, INC.

(Translation of registrant’s name into English)

 

Pixie Dust Technologies, Inc.

2-2-1 Yaesu, Chuo-ku
Tokyo, 104-0028, Japan

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

☒ Form 20-F ☐ Form 40-F

 

 

 

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

 

Issuance of Press Release

 

On December 14, 2023, Pixie Dust Technologies, Inc. (the “Company”) issued a press release announcing that a Company-sponsored experiment on the Company’s SonoRepro™ product was recently conducted by Dr. Akinobu Miyata, Director of Miyata Medical Clinic, in collaboration with the Japan Clinical Trial Association (JACTA).

 

The press release furnished in this report as Exhibit 99.1 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, as amended, except to the extent specifically provided in such a filing.

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		Press release of the Company, dated December 14, 2023.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: December 14, 2023	Pixie Dust Technologies, Inc.
	By:	/s/ Yoichi Ochiai
		Name:	Yoichi Ochiai
		Title:	Chief Executive Officer

 

 

Exhibit 99.1 

 

 

 

SonoRepro™ by Pixie Dust Technologies, Inc.

Featured in Medical Practice and New Drugs 2023 Study

 

New Study Showcases Efficacy of SonoRepro™

 

New York, New York and Tokyo, Japan, December 14, 2023 – Pixie Dust Technologies, Inc. (Nasdaq: PXDT) (the “Company”), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that a Company-sponsored experiment on the Company’s SonoRepro™ product was recently conducted by Dr. Akinobu Miyata, Director of Miyata Medical Clinic, in collaboration with the Japan Clinical Trial Association (JACTA).

 

The study, aimed at determining the effects on the scalp and hair when using SonoRepro™ with scalp lotion for 12 weeks, consisted of adult men and women under 49 years old who were concerned about thinning hair. The goal of the study was to utilize a test group and control group to determine whether results were significant.

 

As part of the study, scalp lotion was applied to the top of the head, and ultrasonic waves were irradiated to the scalp by SonoRepro™ to cover the center of the application area. SonoRepro™’s non-contact vibrotactile stimulation is a technology that irritates the skin without physically touching it, using ultrasonic waves transmitted through the air.

 

In comparing the results of the test group with the control group, the outcome revealed that the study participants who received treatment via SonoRepro™ showed a meaningful improvement in hair diameter, head condition, and scalp water content.

 

“The recent study evidenced the efficacy of our technology across both genders and different age groups,” said Pixie Dust Technologies, Inc. CRO Takayuki Hoshi. “Moving forward, we intend to further explore the potential of our wave control technology in the healthcare sector.”

 

Forward-Looking Statements

 

Certain statements contained in this press release are “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the Company’s current expectations or beliefs concerning future events and actual events may differ materially from current expectations. Any such forward-looking statements are subject to various risks and uncertainties, including the strength of the economy, changes to the market for securities, political or financial instability and other factors which are set forth in the Company’s Annual Report on Form 20-F for the year ended April 30, 2023 (File No. 001-41749) filed with the SEC, and in all filings with the SEC made by the Company subsequent to the filing thereof. The Company does not undertake to publicly update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.

 

About Pixie Dust Technologies, Inc.

 

Pixie Dust Technologies, Inc. is a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave technology. The Company is currently focusing on two areas of product development: (1) “Personal Care & Diversity”, where wave control technology is applied to mechanobiology and intervention/assistance in vision, hearing, and touch, and (2) “Workspace & Digital Transformation,” where metamaterials (technology that creates properties through structure rather than material) and solutions to commercial design problems, such as in offices or construction sites, are applied.

 

Pixie Dust Technologies Investor Relations Contact:

 

Email: PXDT_IR@pixiedusttech.com

 

Gateway Group, Inc.

John Yi and Luke Johnson

Email: pixie@gateway-grp.com

 

 

 

 

---